SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Biotech Bay
Desperate But Not Crazy
April 1, 2008
 · 
2 min read
BioCapital
FDA Warns of Tysabri Liver Risk; Biogen Idec, Inc. (Massachusetts) and Elan Corporation PLC Slide on Woes
February 28, 2008
 · 
1 min read
Ringing in the New Year
January 31, 2008
 · 
5 min read
Genetown
BB Biotech AG Invested 9.5% of its Portfolio in Biogen Idec, Inc. (Massachusetts)
October 16, 2007
 · 
1 min read
Job Trends
Beantown/Genetown and Beyond: Biotechnology in Massachusetts
September 13, 2007
 · 
11 min read
Drug Development
No New Brain Infection Cases with MS Drug Biogen Idec, Inc. (Massachusetts)'s Tysabri
August 28, 2007
 · 
1 min read
Genetown
Icahn May Boost Biogen Idec, Inc. (Massachusetts) Stake, Forecasts Takeover
August 27, 2007
 · 
1 min read
Biotech Beach
The Day In Review: Genentech, Inc. Adds To Pipeline, Again
January 9, 2007
 · 
1 min read
Genetown
The Day In Review: Cambrex Corporation Sells Bio Businesses For $460 Million
October 24, 2006
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
May 22, 2026
 · 
15 min read
Press Releases
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer’s Pathologies in Biogen’s Phase 2 Tau Study
May 14, 2026
 · 
3 min read
Press Releases
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
May 14, 2026
 · 
8 min read
Press Releases
Biogen Completes Acquisition of Apellis Pharmaceuticals
May 14, 2026
 · 
21 min read
Press Releases
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
May 14, 2026
 · 
11 min read
Press Releases
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
May 8, 2026
 · 
18 min read
Press Releases
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
April 20, 2026
 · 
14 min read
Press Releases
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer’s Disease at the 78th American Academy of Neurology’s Annual Meeting
April 9, 2026
 · 
10 min read
Press Releases
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
April 7, 2026
 · 
3 min read
Press Releases
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026
 · 
32 min read
Load More